Block Admission and ISIN update

Medgenics, Inc.
("Medgenics" or the "Company")

4 December 2007

Medgenics is the holding company of a clinical trial stage biopharmaceutical
group with operations primarily in Israel and which is planning to commence
testing the safety and efficacy of its proprietary Biopump in 2008. The Company
has made an application to the London Stock Exchange for a block admission (in
relation to the Company's outstanding Warrants and Options under the Share
Incentive Plan) to trading on AIM on 4 December 2007 for 20,818,683 Common
Shares of US $0.0001 each which are subject to Regulation S restrictions and
which represent 20 per cent. of the Company's issued Common Shares on Admission.

The Company will notify the public through an RNS announcement the information
required in Schedule Eight of the AIM Rules immediately following 30 June and 31
December in each year. The next notification will be for the period 4 December
2007 to 31 December 2007.

The Company is also announcing that all of its Common Shares on Admission will
be issued under the ISIN USU582411075 and subject to Regulation S restrictions.
This is a change of ISIN from the number reported in the Admission Document.

Enquiries:

Dr. Andrew L. +972 4 958 8555 Medgenics, Inc. President and CEO
Pearlman

James Pinner or +44 207 512 0191 Blomfield Corporate Finance Limited Nominated Adviser
Alan MacKenzie

Peter Manfield or +44 207 638 5600 SVS Securities plc Brokers
Ian Callaway

Jonathan Shillington or +44 207 638 9571 Citigate Dewe Rogerson Public Relations
Mark Swallow or
Chris Gardner

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024